131 related articles for article (PubMed ID: 9364206)
1. Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice.
Maroulakou IG; Shibata MA; Jorcyk CL; Chen XX; Green JE
Mol Carcinog; 1997 Oct; 20(2):168-74. PubMed ID: 9364206
[TBL] [Abstract][Full Text] [Related]
2. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE
Cancer Res; 1996 Jul; 56(13):2998-3003. PubMed ID: 8674054
[TBL] [Abstract][Full Text] [Related]
3. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage.
Shibata MA; Liu ML; Knudson MC; Shibata E; Yoshidome K; Bandey T; Korsmeyer SJ; Green JE
EMBO J; 1999 May; 18(10):2692-701. PubMed ID: 10329616
[TBL] [Abstract][Full Text] [Related]
4. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene.
Maroulakou IG; Anver M; Garrett L; Green JE
Proc Natl Acad Sci U S A; 1994 Nov; 91(23):11236-40. PubMed ID: 7972041
[TBL] [Abstract][Full Text] [Related]
5. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
[TBL] [Abstract][Full Text] [Related]
6. Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice.
Liu ML; Shibata MA; Von Lintig FC; Wang W; Cassenaer S; Boss GR; Green JE
Oncogene; 2001 Apr; 20(16):2044-9. PubMed ID: 11360188
[TBL] [Abstract][Full Text] [Related]
7. The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice.
Elson A; Deng C; Campos-Torres J; Donehower LA; Leder P
Oncogene; 1995 Jul; 11(1):181-90. PubMed ID: 7624126
[TBL] [Abstract][Full Text] [Related]
8. 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Green JE; Shibata MA; Shibata E; Moon RC; Anver MR; Kelloff G; Lubet R
Cancer Res; 2001 Oct; 61(20):7449-55. PubMed ID: 11606379
[TBL] [Abstract][Full Text] [Related]
9. Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.
Shibata MA; Jorcyk CL; Devor DE; Yoshidome K; Rulong S; Resau J; Roche N; Roberts AB; Ward JM; Green JE
Carcinogenesis; 1998 Jan; 19(1):195-205. PubMed ID: 9472712
[TBL] [Abstract][Full Text] [Related]
10. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
11. The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents.
Gillet R; Grimber G; Bennoun M; Caron de Fromentel C; Briand P; Joulin V
Oncogene; 2000 Jul; 19(31):3498-507. PubMed ID: 10918608
[TBL] [Abstract][Full Text] [Related]
12. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
13. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.
Holzer RG; MacDougall C; Cortright G; Atwood K; Green JE; Jorcyk CL
Breast Cancer Res Treat; 2003 Jan; 77(1):65-76. PubMed ID: 12602905
[TBL] [Abstract][Full Text] [Related]
15. Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis.
Heinlein C; Krepulat F; Löhler J; Speidel D; Deppert W; Tolstonog GV
Int J Cancer; 2008 Apr; 122(8):1701-9. PubMed ID: 18092324
[TBL] [Abstract][Full Text] [Related]
16. SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors.
Tzeng YJ; Zimmermann C; Guhl E; Berg B; Avantaggiati ML; Graessmann A
Oncogene; 1998 Apr; 16(16):2103-14. PubMed ID: 9572491
[TBL] [Abstract][Full Text] [Related]
17. Pathologic progression of mammary carcinomas in a C3(1)/SV40 T/t-antigen transgenic rat model of human triple-negative and Her2-positive breast cancer.
Hoenerhoff MJ; Shibata MA; Bode A; Green JE
Transgenic Res; 2011 Apr; 20(2):247-59. PubMed ID: 20549348
[TBL] [Abstract][Full Text] [Related]
18. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
[TBL] [Abstract][Full Text] [Related]
19. Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors.
Roussos ET; Wang Y; Wyckoff JB; Sellers RS; Wang W; Li J; Pollard JW; Gertler FB; Condeelis JS
Breast Cancer Res; 2010; 12(6):R101. PubMed ID: 21108830
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations are not selected for in simian virus 40 T-antigen-induced tumors from transgenic mice.
Moore M; Teresky AK; Levine AJ; Seiberg M
J Virol; 1992 Feb; 66(2):641-9. PubMed ID: 1370552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
